These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

967 related items for PubMed ID: 29807856

  • 1. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [Abstract] [Full Text] [Related]

  • 2. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
    Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR.
    Cancer; 2020 Jul 15; 126(14):3219-3228. PubMed ID: 32365229
    [Abstract] [Full Text] [Related]

  • 3. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
    Cho BC, Loong HHF, Tsai CM, Teo MLP, Kim HR, Lim SM, Jain S, Olsen S, Park K.
    Curr Oncol; 2022 Mar 21; 29(3):2154-2164. PubMed ID: 35323374
    [Abstract] [Full Text] [Related]

  • 4. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB, Lilo MT, Geddes S, Pallavajjalla A, Askin F, Gabrielson E, Zheng G, Li QK.
    Cancer Cytopathol; 2016 Jul 21; 124(7):485-92. PubMed ID: 27007084
    [Abstract] [Full Text] [Related]

  • 5. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, Zhao J, An T, Duan J, Wu M, Wang J.
    Oncotarget; 2016 Apr 12; 7(15):20810-24. PubMed ID: 26989078
    [Abstract] [Full Text] [Related]

  • 6. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X, Zhang Z, Zheng X, Xie F, Duan F, Jiang L, Chuai S, Han-Zhang H, Han B, Sun J.
    J Thorac Oncol; 2017 Apr 12; 12(4):663-672. PubMed ID: 28007624
    [Abstract] [Full Text] [Related]

  • 7. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB, Welsh A, Chung JH, Pavlick D, Bernicker EH, Creelan BC, Forcier B, Ross JS, Stephens PJ, Ali SM, Dagogo-Jack I, Shaw AT, Li T, Ou SI, Miller VA.
    J Thorac Oncol; 2019 Feb 12; 14(2):255-264. PubMed ID: 30368012
    [Abstract] [Full Text] [Related]

  • 8. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.
    Oncologist; 2016 Jun 26; 21(6):684-91. PubMed ID: 27151654
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.
    J Thorac Oncol; 2017 Jun 26; 12(6):932-942. PubMed ID: 28315738
    [Abstract] [Full Text] [Related]

  • 11. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H, Yang X, Zhang J, Zhang Z, Xu X, Zhang X, Zhang C, Liu D, Yan W, Zhou N, Zhu H, Qian Z, Li Z, Zhang X.
    Sci Rep; 2017 Nov 06; 7(1):14605. PubMed ID: 29097733
    [Abstract] [Full Text] [Related]

  • 12. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y, Zhang FS, Guo L, Ying JM.
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec 08; 47(12):904-909. PubMed ID: 30522169
    [Abstract] [Full Text] [Related]

  • 13. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    Chen H, Wang A, Wang J, He Z, Mao Y, Liu L.
    J Cancer Res Clin Oncol; 2020 Jul 08; 146(7):1867-1876. PubMed ID: 32221744
    [Abstract] [Full Text] [Related]

  • 14. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, Baik CS.
    Clin Lung Cancer; 2020 Nov 08; 21(6):545-552.e1. PubMed ID: 32665165
    [Abstract] [Full Text] [Related]

  • 15. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y, Dong Y, Zhao R, Zhang B, Wang S, Zhang L, Hu M, He Q, Zhang W, Han B.
    Clin Lung Cancer; 2020 Sep 08; 21(5):e355-e362. PubMed ID: 32139332
    [Abstract] [Full Text] [Related]

  • 16. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, Van Meerbeeck J, Lardon F, Rolfo C, Pauwels P.
    Lung Cancer; 2017 May 08; 107():100-107. PubMed ID: 27180141
    [Abstract] [Full Text] [Related]

  • 17. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B, Niu X, Zhang Q, Wang C, Liu B, Yue D, Li C, Giaccone G, Li S, Gao L, Zhang H, Wang J, Yang H, Wu R, Ni P, Wang C, Ye M, Liu W.
    Lung Cancer; 2019 Aug 08; 134():108-116. PubMed ID: 31319968
    [Abstract] [Full Text] [Related]

  • 18. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C, Yang X, Xing W, Yu H, Si T, Guo Z.
    Thorac Cancer; 2020 Mar 08; 11(3):588-593. PubMed ID: 31944608
    [Abstract] [Full Text] [Related]

  • 19. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.
    Ann Oncol; 2019 Feb 01; 30(2):290-296. PubMed ID: 30535340
    [Abstract] [Full Text] [Related]

  • 20. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
    Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R.
    Clin Cancer Res; 2017 Sep 01; 23(17):5101-5111. PubMed ID: 28539465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.